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Background: Exercise limitation is an important issue in patients with chronic obstructive pulmonary disease
(COPD), and it often co-exists with obstructive sleep apnoea (overlap syndrome). This study examined the effects
of nocturnal continuous positive airway pressure (CPAP) treatment on walking capacity in COPD patients with or
without obstructive sleep apnoea.
Methods: Forty-four stable moderate-to-severe COPD patients were recruited and completed this study. They all
underwent polysomnography, CPAP titration, accommodation, and treatment with adequate pressure. The
incremental shuttle walking test was used to measure walking capacity at baseline and after two nights of CPAP
treatment. Urinary catecholamine and heart rate variability were measured before and after CPAP treatment.
Results: After two nights of CPAP treatment, the apnoea-hypopnoea index and oxygen desaturation index
significantly improved in both overlap syndrome and COPD patients, however these changes were significantly
greater in the overlap syndrome than in the COPD group. Sleep architecture and autonomic dysfunction
significantly improved in the overlap syndrome group but not in the COPD group. CPAP treatment was associated
with an increased walking capacity from baseline from 226.4 ± 95.3 m to 288.6 ± 94.6 m (P < 0.05), and decreased
urinary catecholamine levels, pre-exercise heart rate, oxygenation, and Borg scale in the overlap syndrome group.
An improvement in the apnoea-hypopnoea index was an independent factor associated with the increase in
walking distance (r = 0.564).
Conclusion: Nocturnal CPAP may improve walking capacity in COPD patients with overlap syndrome.
Trial registration: NCT00914264
Keywords: Chronic obstructive pulmonary disease, Obstructive sleep apnoea, Walking capacity, Autonomic
dysfunction, Continuous positive airway pressureIntroduction
Mortality due to chronic obstructive pulmonary disease
(COPD) is increasing, and COPD is a serious health bur-
den worldwide. The characteristic physiological impair-
ments are airflow limitation, air-trapping, hyper-inflation,
dyspnoea, and exercise limitation [1]. Patients with
COPD and exercise limitation will adopt a more
sedentary lifestyle and give up the more strenuous phys-
ical activities [2,3], which eventually leads to de-* Correspondence: q8828@ms11.hinet.net
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reproduction in any medium, provided the orconditioning and ultimately further exercise limitation
[4]. Moreover, exercise limitation is associated with
morbidity and mortality [5,6]. As such, finding ways to
break this vicious cycle of exercise limitation is an im-
portant issue in COPD. Exercise limitation is influenced
by age, body weight, dyspnoea sensation, pulmonary
function, skeletal muscles, hypoxemia, cardio-vascular
function, autonomic dysfunction, and emotion [7]. Noc-
turnal intermittent hypoxemia and sleep fragmentation
have also been shown to be associated with impaired
walking performance in older men [8]. In COPD pa-
tients, it has been suggested that hypoxemia during ex-
ercise limits walking performance, but that this is
improved by oxygen supply during exercise [9,10].td. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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fects walking performance remains unclear.
Obstructive sleep apnoea (OSA) is characterized by re-
current pharyngeal collapse with intermittent hypoxemia
during sleep and subsequent repetitive arousal to main-
tain ventilation. Concomitant COPD and OSA, termed
the overlap syndrome, is not rare and affects at least 1%
of the general population [11-13]. Nocturnal continuous
positive airway pressure (CPAP) via a pneumatic splint
is effective in maintaining upper airway patency, and is
standard treatment for OSA [14]. In addition, it can
reverse sleep fragmentation, nocturnal intermittent hyp-
oxemia and autonomic dysfunction. Therefore, it is
reasonable to assume that reversing intermittent hypox-
emia, sleep fragmentation and autonomic dysfunction
will improve walking performance in overlap syndrome
patients. The aim of this study was to clarify whether
walking performance significantly increases in COPD
patients with OSA after nocturnal CPAP treatment.
Materials and methods
This prospective, controlled, observational study was
performed at one sleep centre of a tertiary hospital
(Chang Gung Memorial Hospital) from January 2009 to
May 2012. The local Ethics Committee of Chang Gung
Memorial Hospital approved the research protocol
(NCT00914264) and each patient provided written in-
formed consent.
Subjects
Outpatients with stable COPD were enrolled from the
thorax department of Chang Gung Memorial Hospital.
The inclusion criteria were FEV1/FVC less than 70%, a
smoking history of at least 10 pack-years, and snoring (≥ 3
nights/week). The exclusion criteria were an age younger
than 40 years, bronchiectasis, acute exacerbation within
2 months of the study, renal insufficiency, heart failure,
neuromuscular disease, mood disorder, malignancy, claus-
trophobia, chronic respiratory failure (PaO2 < 60 mmHg
or PaCO2 > 50 mmHg in room air), or sleep disorders
other than OSA.
Study design
This study investigated the effects of two nights of
CPAP treatment on the walking capacity of COPD pa-
tients with or without OSA. All patients underwent
polysomnography on the first night to identify those
with OSA. The incremental shuttle walking test (ISWT)
was then performed by all of the study patients on the
morning of the second day. The patients also underwent
CPAP accommodation and titration according to pub-
lished guidelines to determine the optimal pressure on
the second night [15]. On the third night, the optimal
pressure was applied to all of the study patients. TheISWT was performed again on the morning of the
fourth day. Urine was collected from 10 pm to 7 am on
the first and third nights and sent to the central lab for
catecholamine analysis. The assistants and technicians
who helped with the ISWT and urine analysis were
blinded to the severity of OSA. In addition, the patients
were not aware of the severity of OSA. All patients re-
ceived regular rehabilitation programs, and medical care
did not change during the study period.
Polysomnography and CPAP titration
Polysomnography (Alice 5, Respironics) was performed
on all patients using standard techniques on the first
night. Sleep stages and arousals were scored according
to the AASM criteria [16]. Respiratory efforts were
measured by respiratory plethysmography, and arterial
oxygen saturation was measured by pulse oximetry.
Established criteria were used to score respiratory events
such as hypopnoea, obstructive apnoea, central apnoea,
mixed type apnoea, and Cheyne-Stokes respiration [17].
Apnoea was defined as oronasal flow cessation for more
than 10 seconds. Hypopnoea was defined as a 50% re-
duction in oronasal flow for more than 10 seconds or a
30% reduction followed by arousal or more than 3% de-
crease in SaO2. Based on the polysomnography results,
OSA was defined as an apnoea/hypopnoea index (AHI)
> 15 per hour, of which ≥ 50% were obstructive. CPAP ti-
tration to determine optimal pressure was performed
according to standard guidelines [15].
Heart rate variability and data analysis
After waking, all patients were requested to breathe
regularly and as smoothly as possible in a quiet environ-
ment. CPAP was removed as soon as the patients awoke
in the morning. The first available 5-minute RR data
after waking without CPAP was identified for each pa-
tient on the second and fourth mornings. The details of
the measurement of heart rate variability are described
in the online supplement.
Urinary catecholamine levels
Patients were requested to collect urine samples from
10:00 pm to 7:00 am. The urine samples were collected
in polyethylene containers, acidified with 6 M HCl as a
preservative, and stored at 2-8°C until analysis [18,19].
Urinary levels of catecholamines were measured by high
performance liquid chromatography with a Bio-Rad kit
at the central laboratory of our hospital.
Incremental shuttle walking test
The ISWT was used to determine maximal walking cap-
acity [20,21]. All of the patients performed the ISWT at
least once before the study. The test was then repeated
on the mornings of the second (baseline) and fourth
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the ISWT are described in the online supplement and a
previous study [20].
Statistical analysis
Data were expressed as group percentages (categorical
variables) or mean ± standard deviation (SD, continuous
variables), and compared between pre- and post-CPAP
treatment. Categorical variables were compared by the
chi-square or Fisher’s exact test where appropriate. The
paired t-test was used to compare continuous variables
with normal distribution and paired samples. The
Wilcoxon matched signed rank test was used for paired
samples not distributed normally (all P < 0.05). The
Pearson product correlation coefficient was used to
examine correlations between variables and the change
in walking distance. Multivariate linear regression ana-
lysis was used to determine independent factors affect-
ing the change in walking distance. All analyses were
performed using the SPSS software package version 13.0
and Prism 5, and a P value of less than 0.05 was consid-
ered to indicate statistical significance.
Results
Subject characteristics and polysomnography results
A flow chart of the study design is shown in Figure 1,
and the patients’ characteristics at baseline are shown in
Table 1. Forty-four COPD patients were recruited and
completed this study. There was a higher percentage of
overlap syndrome patients (50%) in this study than in
previous reports, which may be explained by the inclu-
sion criterion of habitual snoring [22]. There were no
significant differences in age, gender, body mass index,
pulmonary function, arterial blood gas, medications and
comorbidities between the groups, however the overlap
syndrome patients seemed to be sleepier and have
poorer sleep quality than the COPD patients. The mean
body mass index in the overlap syndrome group was
24.9 ± 3.5 kg/m2, which is much lower than that
reported in Caucasians, but compatible with Asian OSA
patients [23]. There were no significant differences in
baseline total sleep time, sleep efficiency, mean oxygen
saturation during sleep or sleep architecture between the
groups (Table 2). The mean AHI in the overlap syn-
drome group was 39.2 ± 16.5/h of sleep, indicating that
most of the patients had severe OSA (Table 2). CPAP
treatment did not affect sleep efficiency or total sleep
time in either group, however it significantly decreased
AHI and oxygen desaturation index (ODI) in both
groups. This treatment effect was significantly greater in
the overlap syndrome group than in the COPD group.
CPAP treatment also significantly increased the average
and minimal SaO2 in both groups (Table 2). CPAP treat-
ment improved sleep architecture in the patients withoverlap syndrome, but not in those with COPD, by de-
creasing the proportion of stage 1 sleep (from baseline
23.0 ± 14.0% to 15.4 ± 8.9%, P < 0.05) and increasing slow
wave sleep (from baseline 2.3 ± 3.9% to 5.2 ± 6.1%, P <
0.05) as well as REM stage sleep (from baseline 8.5 ±
7.1% to 16.4 ± 10.3%, P < 0.05) (Table 2).
Heart rate variability and urinary catecholamine levels
Four patients (18.2%) in the overlap syndrome group
and two patients (9.1%) in the COPD group were ex-
cluded from heart rate variability analysis due to ar-
rhythmias. The patients with overlap syndrome (n = 18)
had significantly higher baseline LF (46.6 ± 16.1 nu, P <
0.05), LF/HF (1.8 ± 1.2, P < 0.05) and lower HF (32.2 ±
12.0 nu, P < 0.05) on awakening from sleep than the pa-
tients with COPD (31.8 ± 10.8 nu, 0.9 ± 0.6 and 41.9 ±
12.1 nu, respectively, n = 20) (Table 3). To further inves-
tigate the decrease in sympathetic activity after CPAP
treatment in the overlap syndrome patients, urine cat-
echolamine measurements were added into the protocol
of this study. Urine samples were collected from all of
the study patients except for four patients with overlap
syndrome who refused the urine study. The results re-
vealed higher levels of norepinephrine and epinephrine
in the patients with overlap syndrome (17.0 ± 8.4 μg and
2.4 ± 0.9 μg, respectively, n = 12) than those in the
COPD patients (11.1 ± 5.3 μg and 1.5 ± 0.6 μg, respect-
ively, P < 0.05, n = 12) (Table 3). After CPAP treatment,
LF (31.3 ± 16.7 nu, P < 0.05, n = 18), LF/HF (0.9 ± 0.7,
P < 0.05, n = 18), and urinary levels of norepinephrine
and epinephrine (10.4 ± 6.4 μg and 1.4 ± 0.7 μg, respect-
ively, P < 0.05, n = 12) significantly decreased in the over-
lap syndrome group, but not in the COPD group. HF
also significantly increased after CPAP treatment in the
overlap syndrome group (43.1 ± 19.1 nu, P < 0.05, n =
18), but not in the COPD group (Table 3).
Incremental shuttle walking test
There were no significant differences in baseline walking
distance, pre-exercise or post-exercise Borg scale, oxygen
saturation, heart rate or inspiratory capacity (IC) be-
tween the overlap syndrome and COPD groups (Table 4).
For patients with overlap syndrome, CPAP treatment
significantly increased walking distance (from baseline
from 226.4 ± 95.3 m to 288.6 ± 94.6 m, P < 0.05), and
pre-exercise oxygenation (from baseline 94.5 ± 2.2% to
95.5 ± 1.9%, P < 0.05), and significantly decreased pre-
exercise Borg scale (from 1.5 ± 1.5 to 0.8 ± 1.1, P < 0.05)
and heart rate (from 94.3 ± 17.7/min to 87.3 ± 15.8/min,
P < 0.05) (Table 4). CPAP treatment did not significantly
affect pre-exercise IC or delta-IC in the patients with
overlap syndrome (Table 4). In the patients with COPD,
CPAP treatment also improved walking distance, how-
ever, the increase in walking distance (delta-distance) in
Figure 1 Flow chart of the study design.
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cantly greater than that in the COPD group (15.1 ±
33.6 m). In addition, CPAP treatment did not improve
pre-exercise Borg scale, heart rate, or IC in the COPD
group (Table 4).
Overall, the increase in walking distance (delta-dis-
tance) after CPAP treatment was significantly related to
the attenuation of sleep apnoea/hypopnoea episodes
(delta-AHI) (r = 0.564, P = 0.001) (Figure 2) and de-
saturation episodes (delta-ODI) (r = 0.402, P = 0.007). In
univariate analysis, only delta-AHI and delta-ODI were
significantly correlated with delta-distance (Table E1).
Although the sleep architectures (SWS and REM) were
significant changed after CPAP treatment, there were no
significant correlations between delta-distance and delta-
REM as well as delta-distance and delta-SWS no matter
they were represented in minutes or % of TST. Multi-
variate analysis revealed that delta-AHI was the only in-
dependent factor associated with delta-distance.
In the patients with overlap syndrome, 14 (63.6%) re-
ceived continuous CPAP treatment for three months. Of
these patients, 10 patients had adequate CPAP compli-
ance, which was defined as the use of CPAP > 4 hours
per night and > 5 days per week. Eight (36.4%) patientsrefused continuous CPAP treatment. Three of these
eight patients refused CPAP treatment because of the
personal issues and the other five patients did not feel
much better after two nights of CPAP treatment. The
AHI after three months of follow up was not signifi-
cantly different between the continuous CPAP and non-
CPAP treatment groups (36.2 ± 19.1, n = 10 and 35.6 ±
14.2, n = 8, respectively). In addition, there was no sig-
nificant change in pulmonary function in terms of FEV1
in either the continuous CPAP treatment group (53.9 ±
30.9% predicted, n = 10) or non-CPAP treatment group
(47.4 ± 23.9% predicted, n = 8) when compared to the
baseline values before treatment (52.7 ± 31.3% predicted,
n = 10 and 46.1 ± 24.5% predicted, n = 8, respectively).
The continuous CPAP treatment group maintained the
increase in walking distance with CPAP treatment after
three months of follow-up (57.0 ± 39.2 M) (Online sup-
plement Figure 1). However, the walking distance
returned to baseline in non-CPAP treatment group after
three months of follow-up.
Discussion
This study demonstrated that two nights of nocturnal
CPAP treatment was associated with an improvement in
Table 1 Patient characteristics
Overlap syndrome n = 22 COPD n = 22 p-value
Age 70.0 ± 8.3 71.7 ± 8.5 0.495
Male, n (%) 21 (96.7) 22 (100) 0.999
BMI 24.9 ± 3.5 22.9 ± 3.0 0.054
Smoking, pack-years 52.3 ± 21.5 50.8 ± 26.4 0.837
ESS 12.7 ± 4.5 8.3 ± 3.5 0.004
PSQ 11.8 ± 4.0 7.5 ± 3.7 0.001
Emphysema predominant, n (%) 5 (22.7) 14 (63.6) 0.014
Pulmonary function test
FEV1/FVC 57.5 ± 12.7 54.5 ± 9.6 0.197
FEV1 (L) 1.09 ± 0.51 0.95 ± 0.45 0.227
FEV1 (% predicted) 52.7 ± 28.6 45.1 ± 19.2 0.431
FVC (L) 1.87 ± 0.69 1.70 ± 0.60 0.348
FVC (% predicted) 63.3 ± 25.1 57.2 ± 21.7 0.378
Arterial blood gas
pH 7.4 ± 0.0 7.4 ± 0.0 0.672
PaCO2 (mm Hg) 41.8 ± 3.8 40.6 ± 3.8 0.354
PaO2 (mmHg) 77.5 ± 11.9 79.2 ± 9.0 0.581
Medication
LABA + ICS, n (%) 20 (90.9) 19 (86.4) 0.565
LAMA, n (%) 18 (81.8) 17 (77.3) 0.907
Theophyllines, n (%) 6 (27.3) 2 (9.1) 0.375
Comorbidities
DM, n (%) 0 (0) 1 (4.5) -
HTN, n (%) 10 (45.4) 8 (36.4) 0.348
CAD, n (%) 1 (4.5) 1 (4.5) 0.823
PAOD, n (%) 0 (0) 0 (0) -
Data are presented as mean ± SD, or number (percentage).
BMI body mass index, ESS Epworth sleepiness scale, PSQ Pittsburg sleep quality, FEV1 forced expiratory volume in one second, FVC forced volume capacity, ICS
inhaled corticosteroids, LABA long-acting β2 agonist, LAMA long-acting muscarinic antagonist, DM diabetes mellitus, HTN hypertension, CAD coronary artery
disease, PAOD peripheral arterial occlusion disease.
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addition, the increase in walking distance was clinically
significant and relevant [24]. To date, this is the first
study to report the impact of CPAP treatment on COPD
patients with OSA.
Exercise performance is an important issue for
COPD patients because it is associated with mortality,
hospitalization, and acute exacerbation [2-6]. Poor exer-
cise performance also leads to physical inactivity, and
subsequently to muscle atrophy and de-conditioning,
which causes a further decrease in exercise performance
leading to a vicious cycle [4]. Many factors are associated
with exercise performance including age, body weight,
pulmonary function, oxygenation, dyspnoea sensation,
skeletal muscles, cardiovascular disease, cognitive func-
tion, and obstructive sleep apnoea [7,8,25]. Patients with
heart failure, renal insufficiency, neuromuscular disease,mood or sleep disorders other than OSA, and chronic
respiratory failure were excluded from this study so as to
focus on the effects of OSA on the walking capacity of
COPD patients.
Hypoxemia, one of the cardinal features of OSA, is
known to be more severe in overlap syndrome than in
either individual syndrome, and this was also found in
the current study. In an animal study, chronic intermit-
tent hypoxemia was found to increase diaphragmatic
and limb muscle fatigue in rats [26]. In humans, inspira-
tory muscle dysfunction has been noted in severe
obstructive sleep apnoea [27]. This suggests that inter-
mittent hypoxemia impairs muscle function including
accessory muscles, diaphragm and limb muscles. More-
over, skeletal muscle atrophy and dysfunction, a com-
mon complication in COPD, contribute to increased
nocturnal hypoxemia. The use of nocturnal CPAP to
Table 2 Polysomnographic report: patients with and without CPAP treatment
Overlap syndrome COPD
n = 22 n = 22
Baseline With CPAP P Baseline With CPAP P †P
Total sleep time (minutes) 294.3 ± 80.5 290.1 ± 94.9 0.758 287.8 ± 77.9 273.2 ± 71.7 0.408 0.760
Sleep efficiency (%) 67.2 ± 12.8 68.6 ± 14.3 0.833 66.3 ± 14.2 65.2 ± 12.9 0.650 0.699
AHI event. h-1 39.2 ± 16.5 4.6 ± 2.9 0.001 7.5 ± 4.1* 1.6 ± 1.4 0.001 0.001
ODI event. h-1 20.4 ± 16.2 3.1 ± 2.9 0.001 3.1 ± 2.2* 0.9 ± 1.1 0.001 0.001
Average SaO2% 93.3 ± 2.2 94.5 ± 1.7 0.011 93.8 ± 2.0 94.9 ± 2.1 0.001 0.866
Lowest SaO2% 80.3 ± 8.8 89.3 ± 3.9 0.001 87.0 ± 4.6* 90.2 ± 4.3 0.005 0.089
Wake% 26.6 ± 10.3 21.8 ± 13.7 0.211 25.5 ± 14.2 26.9 ± 12.7 0.578 0.124
N1% 23.0 ± 14.0 15.4 ± 8.9 0.010 20.3 ± 14.1 16.5 ± 8.7 0.079 0.296
N2% 39.5 ± 12.6 41.2 ± 14.9 0.700 34.0 ± 11.8 33.2 ± 11.6 0.941 0.751
N3% 2.3 ± 3.9 5.2 ± 6.1 0.001 7.5 ± 9.4 9.2 ± 11.4 0.235 0.191
REM% 8.5 ± 7.1 16.4 ± 10.3 0.004 12.2 ± 7.7 13.9 ± 7.5 0.144 0.026
CPAP pressure (cm H2O) 6.8 ± 1.8 4.9 ± 0.9*
*P < 0.05; when compared with baseline overlap syndrome group.
P values represent comparisons between baseline and with CPAP in each corresponding group.
†P values represent comparisons with regards to the changes with CPAP treatment between overlap syndrome and COPD in each corresponding group.
AHI apnoea/hypopnea index, ODI oxygen desaturation index, SWS slow wave sleep, REM rapid eye movement, CPAP continuous positive airway pressure.
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etal muscle dysfunction, which may in turn improve the
walking capacity in patients with overlap syndrome.
Sleep deprivation has been documented to be associ-
ated with poor exercise performance [28]. In addition,
poor exercise performance has also been reported in pa-
tients with OSA, which is characterised by sleep frag-
mentation, worsened sleep architecture, and subjective
daytime sleepiness [29]. Similar results were also demon-
strated in this study; however, there was no significant
association between the increase in walking distance
(delta-distance) after CPAP treatment and the improve-
ment in sleep architecture. The existence of ß-errors is
possible, and further large-scale studies are needed to
validate our findings.Table 3 Heart rate variability and urine catecholamine: patien
Heart rate variability
Overlap syndrome n = 18#
Baseline With CPAP
LF (nu) 46.6 ± 16.1 31.3 ± 16.7
HF (nu) 32.2 ± 12.0 43.1 ± 19.1
LF/HF 1.8 ± 1.2 0.9 ± 0.7
Urine catecholamines
Overlap syndrome n = 12$
Baseline With CPAP
Norepinephrine, ug 17.0 ± 8.4 10.4 ± 6.4
Epinephrine, ug 2.4 ± 0.9 1.4 ± 0.7
*P < 0.05; when compared with baseline overlap syndrome group.
P values represent comparisons between before and after CPAP in each correspond
LF low frequency, HF high frequency nu normalized unit.Autonomic dysfunction, another cardinal feature of
OSA, can be reversed by CPAP, and is also noted during
peak exercise in COPD patients [30,31]. In this study,
we found that the patients with overlap syndrome had
higher LF, LF/HF ratio, urine norepinephrine and epi-
nephrine levels compared to the COPD patients,
suggesting that a higher sympathetic activity exists in pa-
tients with overlap syndrome. This autonomic dysfunc-
tion has a negative impact on the walking performance
of COPD patients with OSA. Increased sympathetic
drive leads to inadequate blood flow, local inflammation,
and abnormal skeletal muscle metabolism, which worsen
the walking capacity of COPD patients [32]. The auto-
nomic dysfunction and urine catecholamine levels in the
patients with overlap syndrome after CPAP treatmentts with and without CPAP treatment
COPD
n = 20@
p Baseline With CPAP p
0.001 31.8 ± 10.8* 28.7 ± 20.4 0.401
0.029 41.9 ± 12.1* 43.6 ± 19.3 0.287




0.003 11.1 ± 5.3* 11.9 ± 7.5 0.485
0.025 1.5 ± 0.6* 1.8 ± 0.8 0.374
ing group.
Table 4 Incremental shuttle walking test: before and after CPAP treatment
Variable Overlap syndrome COPD
n = 22 n = 22
Before After p Before After p †P
CPAP CPAP CPAP CPAP
Distance (metre) 226.4 ± 95.3 288.6 ± 94.6 0.001 257.5 ± 89.1 272.5 ± 98.4 0.035 0.001
Borg scale (pre-exercise) 1.5 ± 1.5 0.8 ± 1.1 0.040 1.4 ± 1.3 0.7 ± 1.1 0.064 0.832
Borg scale (post-exercise) 4.9 ± 0.9 4.8 ± 1.1 0.851 5.0 ± 1.1 4.7 ± 1.2 0.450 0.596
SaO2 (pre-exercise) 94.5 ± 2.2 95.5 ± 1.9 0.014 94.6 ± 2.7 95.3 ± 2.2 0.046 0.351
SaO2 (post-exercise) 88.8 ± 4.4 87.8 ± 6.3 0.827 85.1 ± 6.0 84.6 ± 5.7 0.717 0.972
Heart rate (pre-exercise) 94.3 ± 17.7 87.3 ± 15.8 0.009 93.2 ± 15.6 93.4 ± 16.1 0.999 0.026
Heart rate (post-exercise) 136.3 ± 24.2 125.0 ± 22.8 0.018 125.3 ± 29.3 134.8 ± 29.6 0.135 0.010
Delta-IC (L) −0.04 ± 0.23 −0.08 ± 0.17 0.489 −0.13 ± 0.21 −0.12 ± 0.24 0.979 0.548
IC pre-exercise (L) 1.37 ± 0.48 1.44 ± 0.48 0.184 1.34 ± 0.42 1.32 ± 0.42 0.687 0.171
IC post-exercise (L) 1.33 ± 0.48 1.36 ± 0.46 0.586 1.21 ± 0.42 1.20 ± 0.49 0.672 0.225
P values represent comparisons between before and after CPAP in each corresponding group.
†P values represent comparisons with regards to the changes with CPAP treatment between overlap syndrome and pure COPD in each corresponding group.
IC inspiratory capacity.
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COPD patients, indicating that CPAP reversed the auto-
nomic dysfunction mostly caused by OSA. The signifi-
cant decrease in pre-exercise heart rate after CPAP
treatment in the patients with overlap syndrome may
also represent an improvement in autonomic dysfunc-
tion after CPAP treatment. However, the extent to which
this autonomic dysfunction affected the exercise capacity
of the overlap syndrome patients is unknown.
CPAP treatment has been reported to improve survival
in patients with overlap syndrome [33], and in this study
we found that CPAP treatment improved the walkingFigure 2 Correlation between the changes in apnoea-
hypopnoea index (delta-AHI) and the changes in walking
distance (delta-distance) with CPAP treatment in the patients
with overlap syndrome.capacity in the patients with overlap syndrome. Whether
this improvement in exercise capacity can be translated into
an improvement in the mortality rate as reported previously
[5,6,34] warrants a prospective, multi-center study with a
larger study population and a longer observation time.
For the issues about the imbalance of emphysema
component between groups are needed to be further dis-
cussion. All patients enrolled into this study were ar-
ranged HRCT. The severity of emphysema was assessed
by an independent radiologist who was blinded to this
study according to the Goddard scoring system [35]. In
addition, the percentage of emphysema predominant
type in overlap syndrome group is 5/22 (22.7%) and that
in COPD group is 63.6% (14/22) (P = 0.014). Therefore,
the result of this study should be caution to apply to
emphysema predominant type COPD with OSA. In em-
physema predominant type COPD, the lung volume in-
creases, which decreases the severity of obstructive sleep
apnea as Heinzer RC et al. described [36]. In addition,
snores is one of our inclusion criteria that maybe the
reason why the percentage of emphysema predominant
type is relative low in overlap syndrome group.
In conclusion, the presence of OSA in COPD patients
affects sleep architecture, increases hypoxemia episodes
during sleep and increases sympathetic drive on awaken-
ing that together worsen the exercise capacity. Nocturnal
CPAP treatment attenuated OSA-related dysfunction
and then significantly increased the exercise capacity in
the patients with overlap syndrome. However, this study
is an observational study with a small sample size.
Therefore, a large-scale double-blinded randomised con-
trol trial is needed to draw a more definite conclusion.
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